HBV Treatment
Prolonged Entecavir for Slow Responders
- Details
- Category: Approved HBV Drugs
- Published on Friday, 03 June 2011 13:11
- Written by Liz Highleyman
Treatment-naive hepatitis B patients who stay on entecavir (Baraclude) monotherapy despite suboptimal response at 48 weeks are likely to go on to achieve undetectable viral load. 
Is Hepatitis B Under-treated in U.S.?
- Details
- Category: HBV Treatment
- Published on Friday, 20 May 2011 07:48
- Written by Liz Highleyman
As few as 5% of the approximately 1.4 to 2.0 million people with chronic hepatitis B in the U.S. are tested, enter care, and are successfully treated, according to a recent review. 
Switch to Lamivudine Not as Effective as Staying on Entecavir
- Details
- Category: Approved HBV Drugs
- Published on Friday, 06 May 2011 09:14
- Written by James Learned
Hepatitis B patients who switch to cheaper lamivudine (Epivir-HBV) after achieving undetectable HBV viral load and normal ALT on entecavir (Baraclude) are more likely to experience viral rebound. 
Tenofovir Improves Outcomes of HBV Acute-on-Chronic Liver Failure
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 10 May 2011 09:06
- Written by Liz Highleyman
Treatment with tenofovir (Viread) lowers HBV viral load, reduces liver injury, and decreases the risk of death in patients with acute-on-chronic liver failure due to hepatitis B reactivation.
HBV Rebound Common in Patients Taking Oral Meds
- Details
- Category: HBV Treatment
- Published on Tuesday, 03 May 2011 09:25
- Written by Wiley-Blackwell
Nearly half of patients taking nucleoside/nucleotide analogs to treat hepatitis B experienced viral breakthrough over 5 years, and about 40% of these were not attributable to drug resistance mutations.
Web Design and Development by